{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:38:39Z","timestamp":1788838719029,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 AI120749-01A1"],"award-info":[{"award-number":["R01 AI120749-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015581","name":"Houston Methodist Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015581","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jconrel.2018.08.010","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T12:21:44Z","timestamp":1533558104000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis"],"prefix":"10.1016","volume":"286","author":[{"given":"Corrine Ying Xuan","family":"Chua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1103-6979","authenticated-orcid":false,"given":"Priya","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ballerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0478-2065","authenticated-orcid":false,"given":"R. Lyle","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas","family":"Gupte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Susnjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lane R.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Folci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly S.","family":"Filgueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Nehete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto C.","family":"Arduino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagannadha K.","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Grattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.08.010_bb0005","series-title":"\u201cGlobal AIDS Update 2016,\u201d (Joint United Nations Programme on HIV\/AIDS, Geneva, Switzerland)","author":"UNAIDS","year":"2016"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0010","series-title":"\u201cPrevention Gap Report,\u201d (Joint United Nations Programme on HIV\/AIDS)","year":"2016"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0015","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv221","article-title":"Is emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection safer than aspirin?","volume":"3","author":"Kojima","year":"2016","journal-title":"Open Forum. Infect. Dis."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0030","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0040","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11096-013-9861-1","article-title":"Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection","volume":"36","author":"Gengiah","year":"2014","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0050","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0055","doi-asserted-by":"crossref","unstructured":"P. L. Anderson et al., Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 4, 151ra125 (2012).","DOI":"10.1126\/scitranslmed.3004006"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0060","series-title":"\u201cPrevention Gap Report,\u201d (Joint United Nations Programme on HIV\/AIDS, Geneva, Switzerland)","author":"UNAIDS","year":"2016"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125363","article-title":"A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% gel (the CHARM-01 study)","volume":"10","author":"McGowan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0070","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s10461-012-0358-z","article-title":"Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial","volume":"17","author":"Pines","year":"2013","journal-title":"AIDS Behav."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0075","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jac\/dks422","article-title":"Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques","volume":"68","author":"Malcolm","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0080","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1128\/AAC.00391-16","article-title":"Combination pod-intravaginal ring delivers antiretroviral agents for HIV prophylaxis: pharmacokinetic evaluation in an ovine model","volume":"60","author":"Moss","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jconrel.2018.08.010_bb0085","doi-asserted-by":"crossref","first-page":"02465","DOI":"10.1128\/AAC.02465-16","article-title":"Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0090","doi-asserted-by":"crossref","first-page":"16145","DOI":"10.1073\/pnas.1311355110","article-title":"Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges","volume":"110","author":"Smith","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088509","article-title":"Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy","volume":"9","author":"Clark","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0100","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1093\/jac\/dku160","article-title":"Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir","volume":"69","author":"Murphy","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0105","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/QAI.0000000000000314","article-title":"Order of orifices: sequence of condom use and ejaculation by orifice during anal intercourse among women: implications for HIV transmission","volume":"67","author":"Gorbach","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0115","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s11095-016-1904-6","article-title":"A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis","volume":"33","author":"Schlesinger","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0120","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0125","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkq447","article-title":"Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection","volume":"66","author":"Anderson","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0135","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1093\/jac\/dku162","article-title":"Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission","volume":"69","author":"Anderson","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0140","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jconrel.2013.09.028","article-title":"Leveraging nanochannels for universal, zero-order drug delivery in vivo","volume":"172","author":"Ferrati","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0145","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1039\/c0lc00013b","article-title":"A robust nanofluidic membrane with tunable zero-order release for implantable dose specific drug delivery","volume":"10","author":"Fine","year":"2010","journal-title":"Lab Chip"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0150","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/s41467-018-04133-8","article-title":"Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale","volume":"9","author":"Bruno","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0155","doi-asserted-by":"crossref","DOI":"10.1088\/0957-0233\/25\/2\/027003","article-title":"Robotic UV-Vis apparatus for long-term characterization of drug release from nanochannels","volume":"25","author":"Geninatti","year":"2014","journal-title":"Measur. Sci. Technol."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)","volume":"32","author":"Hendrix","year":"2016","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0000000000000110","article-title":"Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1","volume":"66","author":"Herold","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0170","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpba.2011.05.039","article-title":"Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS\/MS detection","volume":"56","author":"Bushman","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0175","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1089\/aid.2016.0008","article-title":"Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state","volume":"32","author":"Seifert","year":"2016","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0180","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/jsm.12897","article-title":"The nanochannel delivery system for constant testosterone replacement therapy","volume":"12","author":"Ferrati","year":"2015","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0185","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/ijo.2016.129","article-title":"Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndrome","volume":"40","author":"Filgueira","year":"2016","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0190","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.nano.2017.02.012","article-title":"A pharmacokinetic study of GC-1 delivery using a nanochannel membrane device","volume":"13","author":"Filgueira","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0195","doi-asserted-by":"crossref","DOI":"10.1063\/1.4819156","article-title":"Scaling and crossovers in molecular transport in nano-fluidic systems","volume":"103","author":"Pimpinelli","year":"2013","journal-title":"Appl. Phys. Lett."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0200","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1021\/nn2037863","article-title":"Gated and near-surface diffusion of charged fullerenes in nanochannels","volume":"5","author":"Grattoni","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0205","series-title":"Biomaterials Science","first-page":"697","author":"Colas","year":"2004"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0210","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0142-9612(02)00565-3","article-title":"Biocompatibility and biofouling of MEMS drug delivery devices","volume":"24","author":"Voskerician","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0215","series-title":"Titanium for Medical Applications. Titanium in Medicine: Material Science, Surface Science, Engineering","author":"Williams","year":"2001"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003174","article-title":"Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission","volume":"3","author":"Patterson","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0225","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/adhm.201400348","article-title":"Delivering enhanced testosterone replacement therapy through nanochannels","volume":"4","author":"Ferrati","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0230","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1128\/AAC.00005-16","article-title":"Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment","volume":"60","author":"Custodio","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0235","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01475-16","article-title":"An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection","volume":"61","author":"Mandal","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0240","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/cid\/ciu916","article-title":"Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men","volume":"60","author":"Seifert","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0245","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1128\/AAC.00120-11","article-title":"Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition","volume":"55","author":"de Lastours","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050632","article-title":"Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen","volume":"7","author":"Radzio","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000391","article-title":"Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection","volume":"2","author":"Garcia-Lerma","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0260","first-page":"22","article-title":"Implantable intrathecal pumps for chronic pain: highlights and updates","volume":"48","author":"Knight","year":"2007","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0265","first-page":"62","article-title":"Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas","volume":"27","author":"Renard","year":"2001","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0270","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0275","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1128\/AAC.01151-15","article-title":"Characterization of HIV-1 resistance to tenofovir alafenamide in vitro","volume":"59","author":"Margot","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0280","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2016.05.012","article-title":"High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate","volume":"132","author":"Margot","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050028","article-title":"Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir","volume":"5","author":"Garcia-Lerma","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0290","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/01.qai.0000167155.44980.e8","article-title":"Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens","volume":"39","author":"Hawkins","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0295","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10544-017-0180-5","article-title":"Remote magnetic switch off microgate for nanofluidic drug delivery implants","volume":"19","author":"Farina","year":"2017","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0300","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1039\/C4NR06209D","article-title":"Leveraging electrokinetics for the active control of dendritic fullerene-1 release across a nanochannel membrane","volume":"7","author":"Bruno","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0305","doi-asserted-by":"crossref","first-page":"18718","DOI":"10.1039\/C6NR06235K","article-title":"The active modulation of drug release by an ionic field effect transistor for an ultra-low power implantable nanofluidic system","volume":"8","author":"Bruno","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0310","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-015-0355-4","article-title":"Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges","volume":"75","author":"Krakower","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2018.08.010_bb0315","doi-asserted-by":"crossref","first-page":"21107","DOI":"10.7448\/IAS.19.7.21107","article-title":"Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa","volume":"19","author":"Hosek","year":"2016","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0320","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dewb.12026","article-title":"Ethics of ARV based prevention: treatment-as-prevention and PrEP","volume":"13","author":"Haire","year":"2013","journal-title":"Dev. World Bioeth."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0325","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10461-016-1565-9","article-title":"Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men","volume":"21","author":"Greene","year":"2017","journal-title":"AIDS Behav."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0330","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.addr.2016.02.003","article-title":"Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy","volume":"103","author":"Owen","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.08.010_bb0335","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/COH.0000000000000219","article-title":"The promise and pitfalls of long-acting injectable agents for HIV prevention","volume":"11","author":"Landovitz","year":"2016","journal-title":"Curr. Opin. HIV AIDS"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918304711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918304711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:40:53Z","timestamp":1759160453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918304711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":67,"alternative-id":["S0168365918304711"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.010","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}